title: [New therapies for type 2 diabetes mellitus].
abstract: The increasing prevalence of obesity and type 2 diabetes mellitus (T2DM) has led to a growing interest in the investigation of new therapies. Treatment of T2DM has focused on the insulinopenia and insulin resistance. However, in the last 10 years, new lines of research have emerged for the treatment of T2DM and preclinical studies appear promising. The possibility of using these drugs in combination with other currently available drugs will enhance the antidiabetic effect and promote weight loss with fewer side effects. The data provided by post-marketing monitoring will help us to better understand their safety profile and potential long-term effects on target organs, especially the cardiovascular risk.
authors.affiliation: Servicio de Endocrinología y Nutrición, Hospital Universitari i Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Universitat Autònoma de Barcelona, Campus de Can Ruti, Badalona, Barcelona, España. Electronic address: mpuigd@gmail.com.
authors.forename: Manuel
authors.initials: M
authors.lastname: Puig-Domingo
authors.affiliation: Servicio de Endocrinología y Nutrición, Hospital Universitari i Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Universitat Autònoma de Barcelona, Campus de Can Ruti, Badalona, Barcelona, España.
authors.forename: Silvia
authors.initials: S
authors.lastname: Pellitero
mesh_terms: D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1 / Q000037:antagonists & inhibitors; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D051048:Diacylglycerol O-Acyltransferase / Q000037:antagonists & inhibitors; D018819:Dipeptidyl Peptidase 4 / Q000187:drug effects; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005934:Glucagon / Q000819:agonists; D005941:Glucokinase / Q000187:drug effects; D005943:Gluconeogenesis / Q000187:drug effects; D005947:Glucose / Q000493:pharmacokinetics; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D054795:Incretins; D007333:Insulin Resistance; D049528:Insulin, Long-Acting / Q000627:therapeutic use; D058990:Molecular Targeted Therapy; D009765:Obesity / Q000150:complications / Q000188:drug therapy; D025481:Phosphofructokinase-2 / Q000037:antagonists & inhibitors; D051247:Sodium-Glucose Transport Proteins / Q000037:antagonists & inhibitors; D015431:Weight Loss; D000097789:Glucagon-Like Peptide-1 Receptor Agonists; D000067757:Glucagon-Like Peptide-1 Receptor
chemical_list: D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1; D019440:Anti-Obesity Agents; D051048:Diacylglycerol O-Acyltransferase; D018819:Dipeptidyl Peptidase 4; D015507:Drugs, Investigational; D004791:Enzyme Inhibitors; D005934:Glucagon; D005941:Glucokinase; D005947:Glucose; D007004:Hypoglycemic Agents; D054795:Incretins; D049528:Insulin, Long-Acting; D025481:Phosphofructokinase-2; D051247:Sodium-Glucose Transport Proteins; D000097789:Glucagon-Like Peptide-1 Receptor Agonists; C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; C468386:HSD11B1 protein, human; C042807:DPP4 protein, human
keywords: Diabetes tipo 2; Future; Futuro; Tratamiento; Treatment; Type 2 diabetes mellitus